{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:29Z","timestamp":1786119209318,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/ftd.0b013e31815c15f3","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T21:16:39Z","timestamp":1236201399000},"page":"781-788","source":"Crossref","is-referenced-by-count":17,"title":["Population Pharmacokinetic Model of Carbamazepine Derived from Routine Therapeutic Drug Monitoring Data"],"prefix":"10.1097","volume":"29","author":[{"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru\u017eica","family":"Veli\u010dkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Pokrajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Mrhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iztok","family":"Grabnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy.","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"R7-10-20210129","first-page":"169","article-title":"Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.","volume":"5","author":"Konsil","year":"2002","journal-title":"J Pharm Pharmaceut Sci"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2125.1998.00769.x","article-title":"Therapeutic drug monitoring-antiepileptic drugs.","volume":"46","author":"Eadie","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/j.1552-4604.1996.tb04246.x","article-title":"Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data.","volume":"36","author":"Yukawa","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinthera.2005.05.001","article-title":"Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.","volume":"27","author":"Carlsson","year":"2005","journal-title":"Clin Ther"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s002280100300","article-title":"Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients.","volume":"57","author":"Deleu","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","article-title":"Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.","volume":"29","author":"Jiao","year":"2004","journal-title":"J Clin Pharmacol Ther"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","article-title":"Population pharmacokinetics of carbamazepine in Chinese epilepsy patients.","volume":"25","author":"Jiao","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011569703060","article-title":"Population pharmacokinetic modelling of steady state carbamazepine clearance in children, adolescents, and adults.","volume":"28","author":"Reith","year":"2001","journal-title":"J Pharmacokinet Pharmacodynam"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.0306-5251.2001.01396.x","article-title":"Population pharmacokinetics of carbamazepine in Singapore epileptic patients.","volume":"51","author":"Chan","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2710.2006.00717.x","article-title":"Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.","volume":"31","author":"Bondareva","year":"2006","journal-title":"J Clin Pharmacol Ther"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2710.2001.00348.x","article-title":"Population pharmacokinetic modeling of Carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage.","volume":"26","author":"Bondareva","year":"2001","journal-title":"J Clin Pharmacol Ther"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00004714-200112000-00008","article-title":"Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients.","volume":"21","author":"Yukawa","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.","volume":"5","author":"Sheiner","year":"1977","journal-title":"J Pharmacokinet Biopharmacol"},{"key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01061870","article-title":"Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.","volume":"11","author":"Sheiner","year":"1983","journal-title":"J Pharmacokinet Biopharmacol"},{"key":"R26-10-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01059771","article-title":"Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.","volume":"21","author":"Wade","year":"1993","journal-title":"J Pharmacokinet Biopharmacol"},{"key":"R27-10-20210129","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1177\/0091270003258670","article-title":"Considerations in analysing single-trough concentrations using mixed-effects modeling.","volume":"43","author":"Booth","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R30-10-20210129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance.","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharmacol"},{"key":"R31-10-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00271363","article-title":"Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.","volume":"44","author":"Miller","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"R32-10-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","article-title":"Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analysis.","volume":"32","author":"Ahn","year":"2005","journal-title":"J Pharmacokinet Pharmacodynam"},{"key":"R33-10-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007691-198512000-00004","article-title":"Serum concentrations of valproic acid: influence of dose and comedication.","volume":"7","author":"May","year":"1985","journal-title":"Ther Drug Monit"},{"key":"R34-10-20210129","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1528-1157.1998.tb01299.x","article-title":"Carbamazepine intoxication with negative myoclonus after the addition of clobazam.","volume":"39","author":"Genton","year":"1998","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e31815c15f3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:44:50Z","timestamp":1786038290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200712000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31815c15f3","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}